Tags:
Don't quote me on the 200 mg - what Dr. Hoffman told me exactly was that the highest UK dosage was 1/10th the dose that worked in the dogs. I thought the highest UK dosage was 20 mg, so I just assumed.
Ofelia - since the money came from the DOD grant, I'm guessing they didn't have it otherwise. Which makes it even more stupid to waste money repeating existing trials.
On another note, Paul - can you please come and organize our garage?
Don't quote me on the 200 mg - what Dr. Hoffman told me exactly was that the highest UK dosage was 1/10th the dose that worked in the dogs. I thought the highest UK dosage was 20 mg, so I just assumed.
Ofelia - since the money came from the DOD grant, I'm guessing they didn't have it otherwise. Which makes it even more stupid to waste money repeating existing trials.
On another note, Paul - can you please come and organize our garage?
More delays...
http://www.avibio.com/duchenne_muscular_dystrophy.php
In addition, AVI has now started the comprehensive series of preclinical tests necessary before a US study with AVI-4658 can be undertaken. The results from these studies will need to be reviewed by the FDA before a US study can start. It is hoped that the US study could start in early 2010.
AVI is advancing a second product, targeting exon 50, and has now started a similar series of preclinical studies with AVI-5038. While these studies are underway, AVI anticipates having discussions with the Regulatory Authorities about plans to start clinical work with AVI-5038. This additional regulatory dialog could help with planning for candidates to skip other common deletions. The early results from our PMO program (with AVI-4658) should help us to streamline this PPMO program; we hope to start a clinical study in mid 2010.
AVI is examining other target deletions with the hope of developing the best candidates for treating these target deletions.
Time to start packing for the UK. Recently we asked Dr Flanigan's opinion about who will come in first - Prosensa or AVI. He said Prosensa. Looks like he might be right.
Thanks for bringing this tidbit to our attention Ofelia. Even tho it isn't great news we still need to know how things are coming along.
cheryl
Ofelia Marin said:More delays...
http://www.avibio.com/duchenne_muscular_dystrophy.php
In addition, AVI has now started the comprehensive series of preclinical tests necessary before a US study with AVI-4658 can be undertaken. The results from these studies will need to be reviewed by the FDA before a US study can start. It is hoped that the US study could start in early 2010.
AVI is advancing a second product, targeting exon 50, and has now started a similar series of preclinical studies with AVI-5038. While these studies are underway, AVI anticipates having discussions with the Regulatory Authorities about plans to start clinical work with AVI-5038. This additional regulatory dialog could help with planning for candidates to skip other common deletions. The early results from our PMO program (with AVI-4658) should help us to streamline this PPMO program; we hope to start a clinical study in mid 2010.
AVI is examining other target deletions with the hope of developing the best candidates for treating these target deletions.
Does this only work with deletions? My son has a duplication of 45 will he be an eligible canidate?
cheryl cliff said:Time to start packing for the UK. Recently we asked Dr Flanigan's opinion about who will come in first - Prosensa or AVI. He said Prosensa. Looks like he might be right.
Thanks for bringing this tidbit to our attention Ofelia. Even tho it isn't great news we still need to know how things are coming along.
cheryl
Ofelia Marin said:More delays...
http://www.avibio.com/duchenne_muscular_dystrophy.php
In addition, AVI has now started the comprehensive series of preclinical tests necessary before a US study with AVI-4658 can be undertaken. The results from these studies will need to be reviewed by the FDA before a US study can start. It is hoped that the US study could start in early 2010.
AVI is advancing a second product, targeting exon 50, and has now started a similar series of preclinical studies with AVI-5038. While these studies are underway, AVI anticipates having discussions with the Regulatory Authorities about plans to start clinical work with AVI-5038. This additional regulatory dialog could help with planning for candidates to skip other common deletions. The early results from our PMO program (with AVI-4658) should help us to streamline this PPMO program; we hope to start a clinical study in mid 2010.
AVI is examining other target deletions with the hope of developing the best candidates for treating these target deletions.
© 2023 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service